相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Review
Cell Biology
Julia Y. Tsang et al.
Summary: TNBC is a major challenge in breast cancer management due to its heterogeneity and diversity. Expression profiling has identified at least four predominant subtypes with specific genomic alterations and tumor microenvironment. Recognizing these subtypes can improve prognosis and guide treatment decisions.
Review
Oncology
Claudette Falato et al.
Summary: Traditionally, breast cancer classification has relied on the expression of immunohistochemical bio-markers available in clinical practice. However, intrinsic molecular subtypes based on gene expression have been identified and show different characteristics compared to IHC-based subgroups. Hormone receptor-positive tumors can demonstrate non-luminal biology, which has prognostic value and impacts sensitivity to treatment. Genomic instability, cell plasticity, treatment selective pressure, and tumor microenvironment all contribute to the diversity observed between primary and metastatic breast cancer. This review focuses on hormone receptor-positive/HER2-negative advanced breast cancer and discusses the distribution and clinical behavior of intrinsic subtypes, as well as ongoing clinical trials investigating their predictive and prognostic value for routine care.
CANCER TREATMENT REVIEWS
(2023)
Review
Oncology
Chakrabhavi Dhananjaya Mohan et al.
Summary: Signal transducer and activator of transcription 3 (STAT3) is a crucial transcription factor involved in various human malignancies. Its activation promotes tumor progression, while inhibiting STAT3 signaling can effectively suppress tumor growth. This review provides a comprehensive overview of the mechanisms of STAT3 signal transduction, its negative regulators, the role of STAT3 in oncogenesis, and the inhibition of STAT3 signaling by natural compounds with potential anti-tumor activity.
SEMINARS IN CANCER BIOLOGY
(2022)
Review
Oncology
Dario Trapani et al.
Summary: Breast cancer is the leading cause of disability and mortality among women worldwide, with disparities in mortality rates between different countries. Investing in breast cancer control and expanding treatment capacity can improve population health. The World Health Organization has launched a global initiative to address these disparities.
CANCER TREATMENT REVIEWS
(2022)
Article
Oncology
Zhan Hua et al.
Summary: Triple-negative breast cancer (TNBC) is a type of breast cancer that lacks effective therapeutic targets and has a poorer prognosis compared to other types of breast cancer. TNBC is highly heterogeneous and can include rare cancer stem cells (CSCs) that contribute to treatment resistance. Single cell analysis technologies offer insights into the role of CSCs in TNBC and their potential as therapeutic targets.
SEMINARS IN CANCER BIOLOGY
(2022)
Article
Oncology
Umar Mehraj et al.
Summary: Tumor heterogeneity is a critical issue in the treatment of triple-negative breast cancer (TNBC), a highly diverse and aggressive subtype of cancer. Chemokines play a significant role in regulating TNBC heterogeneity. Understanding the chemokine networks involved in TNBC can lead to the development of effective therapeutic strategies.
SEMINARS IN CANCER BIOLOGY
(2022)
Review
Oncology
Zhixian Chen et al.
Summary: Protein arginine methyltransferase 6 (PRMT6) is involved in the epigenetic regulation of gene expression and plays various roles in different cancers. It has been identified as a potential therapeutic target for anti-tumor treatment. This review summarizes the current understanding of PRMT6's function, structure, and its role in cancer, as well as the mechanisms behind its effects.
FRONTIERS IN ONCOLOGY
(2022)
Article
Pharmacology & Pharmacy
Mehrdokht Sadrkhanloo et al.
Summary: Epithelial-to-mesenchymal transition (EMT) mechanism is responsible for tumor metastasis and inhibition of this process improves prognosis. STAT3 signaling is shown to promote EMT-mediated cancer migration and invasion, and its inhibition suppresses cancer metastasis and improves therapy response.
PHARMACOLOGICAL RESEARCH
(2022)
Review
Oncology
Yun Li et al.
Summary: Triple-negative breast cancer (TNBC) is a highly malignant subtype of breast cancer with a poor prognosis. Current treatment options are limited, but targeted therapies focusing on DNA repair pathways, androgen receptor signaling pathways, kinases, and immunotherapy have shown promise.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2022)
Review
Pharmacology & Pharmacy
Jae Young So et al.
Summary: This review discusses current therapies, studies in treatment resistance and relapse, including recent single-cell sequencing data, for triple-negative breast cancer (TNBC). It also examines changes in the transcriptome and epigenome of TNBC, mechanisms regulating the immune microenvironment, and provides new perspectives on patient stratification and treatment options.
PHARMACOLOGY & THERAPEUTICS
(2022)
Review
Oncology
Grace L. Wong et al.
Summary: Breast cancer is a common and deadly disease in women, and the STAT family of transcription factors, especially STAT3, plays a critical role in its development and progression. Targeting STAT proteins for cancer treatment presents significant opportunities and challenges.
SEMINARS IN CANCER BIOLOGY
(2022)
Article
Cell Biology
Minghao Yang et al.
Summary: This study found that TIPE1 expression is decreased in osteosarcoma tissues and is negatively related to tumor stage and size. TIPE1 inhibits osteosarcoma carcinogenesis and metastasis by inhibiting PRMT1-mediated STAT3 arginine methylation. These findings provide a potential molecular target for the treatment of osteosarcoma.
CELL DEATH & DISEASE
(2022)
Review
Oncology
Ruoxi Hong et al.
Summary: Breast cancer is the most common cancer worldwide, and treatment strategies vary by molecular features. Early-stage breast cancer can be cured with local-regional therapies, while advanced breast cancer is considered incurable. Innovative technologies of precision medicine may guide individualized treatment strategies in the future.
CANCER COMMUNICATIONS
(2022)
Article
Oncology
Hyuna Sung et al.
Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.
CA-A CANCER JOURNAL FOR CLINICIANS
(2021)
Review
Biochemistry & Molecular Biology
Jian Xu et al.
Summary: Arginine methylation is a crucial post-translational modification that influences protein function and has significant implications for cancer therapy. Protein arginine methyltransferases (PRMTs) have been implicated in various cellular processes and are being explored as potential drug targets for cancer treatment, with some inhibitors already in clinical trials.
Article
Biochemistry & Molecular Biology
Tianzhi Huang et al.
Summary: This study reveals that a CK2 alpha-PRMT6-RCC1 signaling axis plays a crucial role in the stem-like properties and tumor biology of GSCs, contributing to chromatin condensation, mitosis, and overall malignancy in GBM. EPZ020411, a specific small-molecule inhibitor for PRMT6, shows potential as a therapeutic target for treating GBM by suppressing RCC1 arginine methylation and enhancing the efficacy of radiotherapy against GSC brain tumor xenografts.
Review
Biotechnology & Applied Microbiology
Qin Wu et al.
Summary: PRMTs are emerging as attractive therapeutic targets due to their regulation of essential biological processes such as transcription, splicing, RNA biology, DNA damage response, and cell metabolism, which are often disrupted in diseases. Understanding how these enzymes support cancer cell growth in specific metabolic contexts or in the presence of certain mutations has provided the rationale for targeting them in oncology, with ongoing inhibitor development and in-depth mechanistic investigations guiding future clinical development.
NATURE REVIEWS DRUG DISCOVERY
(2021)
Review
Cell Biology
Jia-hui Ma et al.
CELL COMMUNICATION AND SIGNALING
(2020)
Article
Oncology
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS
(2018)
Article
Biochemistry & Molecular Biology
Lifeng Huang et al.
NUCLEIC ACIDS RESEARCH
(2018)
Article
Biochemistry & Molecular Biology
Wei-Wei Yan et al.
Article
Biochemistry & Molecular Biology
Jiawen Huang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY
(2015)
Review
Oncology
Vandana G. Abramson et al.
Article
Oncology
Carol DeSantis et al.
CA-A CANCER JOURNAL FOR CLINICIANS
(2014)
Article
Biochemistry & Molecular Biology
Hye-Sook Han et al.
Article
Biochemistry & Molecular Biology
Sameer Phalke et al.
NUCLEIC ACIDS RESEARCH
(2012)
Article
Cardiac & Cardiovascular Systems
Hiroaki Iwasaki et al.
CIRCULATION RESEARCH
(2010)
Article
Biochemistry & Molecular Biology
Matthew J. Harrison et al.
NUCLEIC ACIDS RESEARCH
(2010)
Article
Cell Biology
Dawin Hyllus et al.
GENES & DEVELOPMENT
(2007)
Article
Multidisciplinary Sciences
Ernesto Guccione et al.
Article
Virology
Baode Xie et al.
JOURNAL OF VIROLOGY
(2007)
Article
Biochemistry & Molecular Biology
N El-Andaloussi et al.
Article
Biochemistry & Molecular Biology
W Komyod et al.
JOURNAL OF BIOLOGICAL CHEMISTRY
(2005)
